Kimyrsa FDA Approval History
Last updated by Judith Stewart, BPharm on April 1, 2021.
Kimyrsa (oritavancin) is a lipoglycopeptide antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSI) caused by designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
- Kimyrsa is a long-acting, single-dose antibiotic administered by intravenous infusion over 1 hour.
- Kimyrsa is the second oritavancin product to be approved by the FDA after the approval of Orbactiv in 2014. Orbactiv is administered as a single-dose intravenous infusion over 3 hours.
- Common adverse reactions in people treated with oritavancin include headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
Development timeline for Kimyrsa
|Mar 15, 2021
|Approval FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.